LeBlanc, Michel meet with pharma sector as U.S. buckles down on cutting drug prices

U.S. President Donald Trump is pushing the sector to negotiate for drug prices similar to those in Canada, which could impact whether companies choose to list their medicines here.
Canada-U.S. Trade Dominic LeBlanc, left, and Health Minister Marjorie Michel met on Feb. 23 with Innovative Medicines Canada and pharmaceutical firm representatives to discuss the U.S.’s most favoured nation approach, and the upcoming Canada-United States-Mexico Agreement review.

United States President Donald Trump’s efforts to reset how pharmaceutical firms negotiate drug prices with his government—and the consequences for countries including Canada—were recently discussed at an in-person meeting between pharmaceutical representatives, Canada...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.


Already a Subscriber?

Get Today's Headlines Newsletter

Wake up to the day's top political and policy headlines. Weekday Mornings.


By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

MORE News

MOST POPULAR

RELATED STORIES

MORE Feature

RELATED STORIES

MORE Feature

RELATED STORIES